Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting.
<h4>Purpose</h4>To establish a baseline for care and overall survival (OS) based upon contemporary first-line treatments prescribed in the era before the introduction of immune checkpoint inhibitors, for people with metastatic non-small cell lung cancer (NSCLC) without common actionable...
| Autori principali: | , , , , , , |
|---|---|
| Natura: | Articolo |
| Lingua: | English |
| Pubblicazione: |
Public Library of Science (PLoS)
2017-01-01
|
| Serie: | PLoS ONE |
| Accesso online: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0178420&type=printable |